William Blair & Company’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

William Blair & Company’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28	Closed	-$1.17K	–	2006
2026 Q1	$1.17K	Buy	+28	New	+$1.15K	﹤0.01%	1905

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

William Blair & Company's BBC Position: Q2 2026 in Review

William Blair & Company sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026, closing a stake of 28 shares — an estimated $1.17K sold.

William Blair & Company first reported a position in BBC in Q1 2026 and held it in 1 quarter. The position peaked at $1.17K in Q1 2026. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

William Blair & Company reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2026 after selling out during the quarter.
William Blair & Company sold 28 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $1.17K.
William Blair & Company first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2026 and held it in 1 quarter.
William Blair & Company's Virtus Biotech Clinical Trials ETF position peaked at $1.17K in Q1 2026.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.